TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: About half of CD30+ ALCL patients, especially the ALK‐negative form and an even higher percentage of other CD30+ PTCL subtypes, relapse after front‐line treatment and consolidation with ASCT [152, 153, 154].